Detalhe da pesquisa
1.
Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection.
Clin Proteomics
; 19(1): 48, 2022 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36536316
2.
Correction to: Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection.
Clin Proteomics
; 20(1): 16, 2023 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37031204
3.
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
J Clin Invest
; 134(6)2024 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38319732
4.
ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
Cancer Res
; : OF1-OF17, 2023 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37195023
5.
ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.
Cancer Res
; 2023 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37145169
6.
Holding on to Junk Bonds: Intron Retention in Cancer and Therapy.
Cancer Res
; 81(4): 779-789, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33046441
7.
Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma.
Neurooncol Adv
; 3(1): vdab169, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34988452